Efficacy and Biomarker Study of Bevacizumab for Hearing Loss Resulting From Neurofibromatosis Type 2-Associated Vestibular Schwannomas [Urologic Oncology]
Conclusion
Bevacizumab treatment resulted in durable hearing response in 36% of patients with NF2 and confirmed progressive VS-associated hearing loss. Imaging and plasma biomarkers showed promising associations with response that should be validated in larger studies.
Source: Journal of Clinical Oncology - Category: Cancer & Oncology Authors: Blakeley, Ye, Duda, Halpin, Bergner, Muzikansky, Merker, Gerstner, Fayad, Ahlawat, Jacobs, Jain, Zalewski, Dombi, Widemann, Plotkin Tags: Clinical Trials, Brain Tumors, Translational Oncology, Rare tumor types, MRI, Angiogenesis, Neuro Urologic Oncology Source Type: research
More News: Audiology | Avastin | Brain | Brain Cancers | Brain Tumor | Cancer & Oncology | Clinical Trials | Deafness | Hypertension | MRI Scan | Neurofibromatosis | Neurology | Radiography | Study | Toxicology | Urology & Nephrology
MedWorm Privacy Policy
Disclaimer
Copyright © MedWorm 2006-2024